Australian CBD brand, Elixinol, is set to return to the UK market, following a new licensing and distribution agreement with British Cannabis.

In 2021, Elixinol announced plans to cease trading in the UK and European Union in order to focus its attention on the US and Australian markets. The company said that decision was down to the ‘complex and ongoing developments’ within the regulatory environment in the UK.  

The brand is set to continue its presence in the UK thanks to an exclusive Trademark & Know-How License Agreement with the makers of the well-known British pharmacy range, Canabidol.

Both parties say they are committed to investing in a renewed support of the existing Elixinol sales channels, key retail customers and consumers.

A press release from CBD Health Foods, trading as British Cannabis, confirmed the news in December:

“Given the complex and ongoing developments with the regulatory environment in the UK and given Elixinol’s strategic focus on driving profitability, Elixinol made the considered decision in 2021 to cease trading in the UK and EU markets and instead move to an indirect route to market model by seeking a licensing partner in the UK.“

In a statement, Elixinol Global CEO, Oliver Horn, said he was ‘very excited’ to see the brand continue through the British Cannabis network.

“We are delighted about our partnership with British Cannabis who are the most established manufacturer and distributor of branded and white label CBD products in the UK. British Cannabis’ manufacturing capability also allows us to manufacture Elixinol products in the UK and thus create a more efficient supply chain solution. Through the partnership with British Cannabis, UK consumers will now continue to be able to buy their favourite Elixinol products and we are very excited to see the brand continue following many years of building the brand.”

British Cannabis CEO, Tom Whetten, also commented:

“It is an honour to be asked to continue the legacy of Elixinol here in our home market. The prospect of a dynamic partnership between Australia’s leading global CBD range and the UK’s premier manufacturer has excited both myself and our leadership team.”

Established in 2015, British Cannabis is the largest independently owned, producer, manufacturer and distributor of legal cannabis-derived products in the UK.

What about Novel Foods?

British Cannabis says its expanded portfolio, which now includes the Elixinol range, remains dedicated to producing compliant products.

The CEO added:

“With the security of our Novel Foods dossiers, the potential to take this reinforced portfolio to market makes for a very solid proposition for retailers and provides the CBD supplements consumer with great choices.”